VALBIOTIS Selected at the 80th Scientific Sessions of the American Diabetes Association to Present Phase II Clinical Results of TOTUM-63 in Prediabetes
12.6.2020 08:35:00 EEST | Business Wire | Press release
VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL / PEA/SME eligible), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces that the main results of its international Phase II clinical study demonstrating the metabolic benefits of TOTUM-63 in prediabetic patients are being presented at the 80th Scientific Sessions of the American Diabetes Association (ADA).
This is the fourth time that VALBIOTIS has had its work on TOTUM-63 selected by this major congress, which is being held from 12 to 16 June this year - in virtual format, due to the COVID-19 health crisis. TOTUM-63's clinical data on carbohydrate metabolism, weight and waist circumference are presented as an e-poster ( www.valbiotis.com/en/scientific-publications ). The presentation to the ADA serves as recognition by the global scientific community of the quality of the results obtained for a groundbreaking treatment to reduce the risk of developing type 2 diabetes. No clinically proven answer exists today for people with prediabetes, a reversible state of impaired glucose metabolism which, without intervention, has a 70 to 90% risk of developing into type 2 diabetes1.
The positive results of this study were announced in two stages (press releases of 3 July 2019 and 2 September 2019). In order to confirm these results on a larger population and to allow healthcare professionals worldwide access to this scientific innovation, VALBIOTIS entered into a global strategic partnership with Nestlé Health Science in early 2020. This agreement covers the development and marketing of TOTUM-63 (press release of 5 February 2020), an innovative and patented combination of five plant extracts.
Prof. Jean-Marie Bard, Hospital Practitioner and Professor of Fundamental and Clinical Biochemistry at the University of Nantes, scientific advisor for the study comments: "The presentation of these results to the ADA marks both a real turning point in health nutrition and the recognition of the clinical efficacy of TOTUM-63. This randomized, placebo-controlled Phase II study showed a significant reduction in fasting blood glucose, its primary endpoint, as well as a significant improvement in glucose tolerance, body weight and waist circumference, secondary endpoints of the study, all known as critical risk factors for developing type 2 diabetes. The data is remarkable for its consistency and the clear metabolic impact demonstrated in 51 subjects, all with abdominal obesity associated with moderate hyperglycemia, 2-hour hyperglycemia (OGTT) and hypertriglyceridemia."
At the end of the 6-month supplementation period, fasting blood glucose levels were significantly reduced in subjects receiving 5 grams per day of TOTUM-63 compared to subjects in the control group receiving 5 grams of placebo (-0.04 ± 0.02 vs. +0.09 ± 0.04 g/L, p<0.05). TOTUM-63 also significantly reduced two-hour blood glucose, or postmeal blood glucose (-0.02 ± 0.07 vs +0.32 ± 0.17 g/L, p<0.05), body weight (-0.07 ± 0.42 vs +1.83 ± 0.57 kg; p<0.05) and waist circumference (-1.67 ± 0.73 vs +2.81 ± 0.65 cm; p<0.001).
These results place TOTUM-63 as the first clinically approved, already marketable product for prediabetic individuals (nearly 1 billion worldwide2) to reduce the risk of developing type 2 diabetes.
Murielle Cazaubiel, Member of the Management Board, Director of Development and Medical Affairs at Valbiotis, declares: "Participating in the ADA is part of an outstanding series of achievements for VALBIOTIS' flagship prediabetes product. In just over a year, TOTUM-63 has been successfully scaled up to industrial production and confirmed its clinical efficacy on several metabolic targets and a number of cardiovascular risk factors. It is now the subject of a global partnership with a major player in the field of health nutrition, responsible for the final phase of its development. The international Phase II/III clinical trial REVERSE-IT (press release of 2 April 2020) co-conducted with Nestlé Health Science will start this year with 600 participants. This trial is designed not only to confirm the positive Phase II results on fasting blood glucose levels, but also to extend evaluation of TOTUM-63 to untreated type 2 diabetics."
ABOUT VALBIOTIS
VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.
VALBIOTIS has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of nutritional health solutions designed to reduce the risk of major metabolic diseases, based on a multi-target approach and made possible by the use of plant-based ingredients.
Its products are intended to be licensed to players in the health world.
VALBIOTIS was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63).
VALBIOTIS is a member of the “BPI Excellence” network and received “Innovative Company“ status awarded by BPI France. Valbiotis has also been awarded “Young Innovative Company” status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). VALBIOTIS is a PEA-SME eligible company.
Find out more about VALBIOTIS: www.valbiotis.com
Name: VALBIOTIS
ISIN code: FR0013254851
Mnemonic code : ALVAL
DISCLAIMER
This press release contains forward-looking statements about VALBIOTIS’ objectives, based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and uncertainties, including those described in the VALBIOTIS registration document, filed with the French Financial Markets Regulator (AMF) on 31 July 2019 (application number R19-030) as well in its supplement approved by the AMF on 9 October 2019. These documents are available on the Company’s website (www.valbiotis.com).
This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, VALBIOTIS’ shares or securities in any country.
1Tabak AJ. et al., Lancet, 2012
2AEC Partners data
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200611005792/en/
Contact information
VALBIOTIS / CORPORATE COMMUNICATION
Carole Rocher / Marc Delaunay
+33 5 46 28 62 58
media@valbiotis.com
ACTIFIN / FINANCIAL COMMUNICATION
Stéphane Ruiz
+33 1 56 88 11 14
sruiz@actifin.fr
MADIS PHILEO / MEDIA RELATIONS
Guillaume De Chamisso
+33 6 85 91 32 56
guillaume.dechamisso@madisphileo.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Canada to Join the NATO Innovation Fund to Advance the Local Defence, Security and Resilience Ecosystem21.11.2026 18:00:00 EET | Press release
Canada announced today it is joining the NATO Innovation Fund, becoming the 25th Allied nation to commit to backing deep tech innovation to address the needs of NATO nations. The Government of Canada is committing EUR 64,590,000 (approximately CAD $100 million) to the firm, with the Business Development Bank of Canada (BDC) holding and managing Canada’s investment in the Fund. This brings total commitments to the NATO Innovation Fund to more than EUR 1.1 billion. Canadian membership will give domestic innovators access to patient capital, opportunities to accelerate the adoption of their technology by governments and businesses across the Alliance, a large network of co-investors, and lessons learned from the NIF’s work to date across 24 participating nations. “Canada has the talent, the innovation, and the ambition to be a global leader in defence and security. The NATO Innovation Fund is helping turn that potential into real capabilities by connecting Canadian innovators with the inv
Persona Earns CEN/TS 18099 High Certification for Injection Attack Detection21.11.2026 16:30:00 EET | Press release
Persona, the leading global identity platform, today announced that its Android SDK has earned CEN/TS 18099 High certification for injection attack detection (IAD). High certification is the top level of the European standard. The evaluation was run by CLR CERT, the certification body of Cabinet Louis Reynaud (CLR) Labs. CLR Labs is accredited under ISO/IEC 17025, the international standard for testing laboratories, and it edits CEN/TS 18099. This certificated injection attack detection is available to all Persona customers and can be activated by working with Persona's team. Injection attacks skip the camera entirely. Instead of holding a photo or mask up to a lens, fraudsters use virtual cameras, emulators and tampered devices to feed stolen, manipulated, or AI-generated media straight into the verification flow. To the system, the result looks like a real live capture, and traditional liveness checks aren't built to catch it. "Our customers are facing more sophisticated deepfakes, f
Verlinvest to Facilitate China Resources’ Full Exit From Oatly20.11.2026 23:30:00 EET | Press release
Verlinvest, the global, family-backed consumer-focused evergreen investment company, today announced it has entered into an agreement to acquire China Resources Enterprise, Limited’s (“China Resources”) indirect interests in Oatly Group AB (publ) (Nasdaq: OTLY) (“Oatly”), the world’s original and largest oat drink company. The transaction builds on Verlinvest’s investment in Oatly since 2016 and reinforces its conviction in the company’s long-term potential. A change in strategic direction of state-owned enterprise China Resources informed its decision to fully exit its investment in Oatly. China Resources worked constructively with Verlinvest to identify the best path for it to do so in recognition of the complexity of their joint holding structure. Under the agreement, Verlinvest will acquire China Resources’ indirect interests in Oatly’s equity and convertible instruments that are currently held through Verlinvest and China Resources’ joint venture vehicle, Nativus Company Limited.
Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 21:54:00 EET | Press release
Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 million people each month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120520968/en/ Picsart Opens the AI Behind Its Platform to Developers & Businesses. They can now build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. As new video and image models launch every few weeks, managing separate APIs, API keys, and billing systems creates a fragmented ecosystem. By offering unified access to creative tools, Picsart Platform eliminates fragmentation for all creators, spanning independent developers and corporate marketing teams and studios, by providing access to over 25
NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 19:45:00 EET | Press release
NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create extraordinary moments for Owners, both in the air and on the ground in Kitzbühel. “Kitzbühel is synonymous
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
